Truncated Pneumolysin from Streptococcus pneumoniae as a TLR4-Antagonizing New Drug for Chronic Inflammatory Conditions
Microbial proteins have recently been found to have more benefits in clinical disease treatment because of their better-developed strategy and properties than traditional medicine. In this study, we investigated the effectiveness of a truncated peptide synthesized from the C-terminal sequence of pneumolysin, i.e., C70PLY4, in Streptococcus pneumoniae, in treating chronic inflammatory conditions. It has been shown that C70PLY4 significantly blocks the transendothelial migration of neutrophils and attenuates the formation of atherosclerotic plaque and the secretion of soluble forms of the intercellular adhesion molecule-1 (ICAM-1), the vascular cell adhesion molecule 1 (VCAM-1), and E-selectin in high-fat-diet/streptozotocin-induced inflammatory rats. The mechanism and the docking simulation analysis further indicated that C70PLY4 might serve as a Toll-like receptor 4 (TLR4) antagonist by competing for the binding site of MD2, an indispensable protein for lipopolysaccharide (LPS)-TLR4 interaction signaling, on the TLR4 structure. Moreover, compared to the full-length PLY, C70PLY4 seems to have no cytotoxicity in human vascular endothelial cells. Our study elucidated a possible therapeutic efficacy of C70PLY4 in reducing chronic inflammatory conditions and clarified the underlying mechanism. Thus, our findings identify a new drug candidate that, by blocking TLR4 activity, could be an effective treatment for patients with chronic inflammatory diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Cells - 9(2020), 5 vom: 09. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chang, Shun-Fu [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 26.02.2021 Date Revised 26.02.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/cells9051183 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM30980549X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM30980549X | ||
| 003 | DE-627 | ||
| 005 | 20231225134723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cells9051183 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1032.xml |
| 035 | |a (DE-627)NLM30980549X | ||
| 035 | |a (NLM)32397494 | ||
| 035 | |a (PII)E1183 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chang, Shun-Fu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Truncated Pneumolysin from Streptococcus pneumoniae as a TLR4-Antagonizing New Drug for Chronic Inflammatory Conditions |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.02.2021 | ||
| 500 | |a Date Revised 26.02.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Microbial proteins have recently been found to have more benefits in clinical disease treatment because of their better-developed strategy and properties than traditional medicine. In this study, we investigated the effectiveness of a truncated peptide synthesized from the C-terminal sequence of pneumolysin, i.e., C70PLY4, in Streptococcus pneumoniae, in treating chronic inflammatory conditions. It has been shown that C70PLY4 significantly blocks the transendothelial migration of neutrophils and attenuates the formation of atherosclerotic plaque and the secretion of soluble forms of the intercellular adhesion molecule-1 (ICAM-1), the vascular cell adhesion molecule 1 (VCAM-1), and E-selectin in high-fat-diet/streptozotocin-induced inflammatory rats. The mechanism and the docking simulation analysis further indicated that C70PLY4 might serve as a Toll-like receptor 4 (TLR4) antagonist by competing for the binding site of MD2, an indispensable protein for lipopolysaccharide (LPS)-TLR4 interaction signaling, on the TLR4 structure. Moreover, compared to the full-length PLY, C70PLY4 seems to have no cytotoxicity in human vascular endothelial cells. Our study elucidated a possible therapeutic efficacy of C70PLY4 in reducing chronic inflammatory conditions and clarified the underlying mechanism. Thus, our findings identify a new drug candidate that, by blocking TLR4 activity, could be an effective treatment for patients with chronic inflammatory diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Toll-like receptor 4 | |
| 650 | 4 | |a chronic inflammatory disease | |
| 650 | 4 | |a microbial protein | |
| 650 | 4 | |a neutrophil activation | |
| 650 | 4 | |a pneumolysin | |
| 650 | 7 | |a Bacterial Proteins |2 NLM | |
| 650 | 7 | |a E-Selectin |2 NLM | |
| 650 | 7 | |a Lipopolysaccharides |2 NLM | |
| 650 | 7 | |a Mutant Proteins |2 NLM | |
| 650 | 7 | |a NF-kappa B |2 NLM | |
| 650 | 7 | |a Streptolysins |2 NLM | |
| 650 | 7 | |a Toll-Like Receptor 4 |2 NLM | |
| 650 | 7 | |a Vascular Cell Adhesion Molecule-1 |2 NLM | |
| 650 | 7 | |a plY protein, Streptococcus pneumoniae |2 NLM | |
| 650 | 7 | |a Intercellular Adhesion Molecule-1 |2 NLM | |
| 650 | 7 | |a 126547-89-5 |2 NLM | |
| 650 | 7 | |a Streptozocin |2 NLM | |
| 650 | 7 | |a 5W494URQ81 |2 NLM | |
| 650 | 7 | |a Extracellular Signal-Regulated MAP Kinases |2 NLM | |
| 650 | 7 | |a EC 2.7.11.24 |2 NLM | |
| 650 | 7 | |a Caspase 3 |2 NLM | |
| 650 | 7 | |a EC 3.4.22.- |2 NLM | |
| 700 | 1 | |a Chen, Cheng-Nan |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Jung-Chung |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Hsin-Ell |e verfasserin |4 aut | |
| 700 | 1 | |a Mori, Shigetarou |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Jia-Je |e verfasserin |4 aut | |
| 700 | 1 | |a Yen, Chia-Kuang |e verfasserin |4 aut | |
| 700 | 1 | |a Hsu, Ching-Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Fung, Chang-Phone |e verfasserin |4 aut | |
| 700 | 1 | |a Chong, Pele Choi-Sing |e verfasserin |4 aut | |
| 700 | 1 | |a Leng, Chih-Hsiang |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Yi-Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Chang, Feng-Yee |e verfasserin |4 aut | |
| 700 | 1 | |a Siu, L Kristopher |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cells |d 2011 |g 9(2020), 5 vom: 09. Mai |w (DE-627)NLM227066421 |x 2073-4409 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2020 |g number:5 |g day:09 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cells9051183 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2020 |e 5 |b 09 |c 05 | ||